Immunoproteomic analysis of the human antibody response to natural tularemia infection with Type A or Type B strains or LVS vaccination

International Journal of Medical Microbiology

Volumn 301, Issue 7, 2011, Pages 591-601

  Fulton, Kelly M ^a   Zhao, Xigeng ^a   Petit, Mireille D ^a   Kilmury, Sara L N ^a   Wolfraim, Lawrence A ^b   House, Robert V ^b   Sjostedt, Anders ^c   Twine, Susan M ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b A CSC Company   (United States)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

Francisella tularensis; Immunoproteomics; Live vaccine strain; Tularemia; Vaccine

Indexed keywords

ANTIBODY; LIVE VACCINE; SUBUNIT VACCINE; TULAREMIA VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY SCREENING; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DATA ANALYSIS; GEOGRAPHY; HEALTH SURVEY; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; PROTEIN ANALYSIS; PROTEOMICS; TULAREMIA;

ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; FRANCISELLA TULARENSIS; HUMANS; PROTEOME; TULAREMIA; VACCINES, ATTENUATED;

EID: 80052740641     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2011.07.002     Document Type: Article

References (39)

1. Burke D.S. Immunization against tularemia: analysis of the effectiveness of live Francisella tularensis vaccine in prevention of laboratory-acquired tularemia. J. Infect. Dis. 1977, 135(1):55-60.
2. Carlsson H.E., Lindberg A.A., Lindberg G., Hederstedt B., Karlsson K.A., Agell B.O. Enzyme-linked immunosorbent assay for immunological diagnosis of human tularemia. J. Clin. Microbiol. 1979, 10(5):615-621.
3. Conlan J.W. Vaccines against Francisella tularensis - past, present and future. Expert Rev. Vaccines 2004, 3(3):307-314.
4. Dennis D.T., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Fine A.D., Friedlander A.M., Hauer J., Layton M., Lillibridge S.R., McDade J.E., Osterholm M.T., O'Toole T., Parker G., Perl T.M., Russell P.K., Tonat K. Tularemia as a biological weapon: medical and public health management. JAMA 2001, 285(21):2763-2773.
5. Dienst F.T. Tularemia: a perusal of three hundred thirty-nine cases. J. La. State Med. Soc. 1963, 115:114-127.
6. Eigelsbach H.T., Hornick R.B., Tulis J.J. Recent studies on live tularemia vaccine. Med. Ann. Dist. Columbia 1967, 36(5):282-286.
7. El Sahly H.M., Atmar R.L., Patel S.M., Wells J.M., Cate T., Ho M., Guo K., Pasetti M.F., Lewis D.E., Sztein M.B., Keitel W.A. Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans. Vaccine 2009, 27(36):4905-4911.
8. Elkins K.L., Cowley S.C., Bosio C.M. Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis live vaccine strain. Microbes Infect. 2003, 5(2):135-142.
9. Ericsson M., Sandstrom G., Sjostedt A., Tarnvik A. Persistence of cell-mediated immunity and decline of humoral immunity to the intracellular bacterium Francisella tularensis 25 years after natural infection. J. Infect. Dis. 1994, 170(1):110-114.
10. Eyles J.E., Unal B., Hartley M.G., Newstead S.L., Flick-Smith H., Prior J.L., Oyston P.C., Randall A., Mu Y., Hirst S., Molina D.M., Davies D.H., Milne T., Griffin K.F., Baldi P., Titball R.W., Felgner P.L. Immunodominant Francisella tularensis antigens identified using proteome microarray. Proteomics 2007, 7(13):2172-2183.
11. Feldman K.A., Stiles-Enos D., Julian K., Matyas B.T., Telford S.R., Chu M.C., Petersen L.R., Hayes E.B. Tularemia on Martha's Vineyard: seroprevalence and occupational risk. Emerg. Infect. Dis. 2003, 9(3):350-354.
12. Felgner P.L., Kayala M.A., Vigil A., Burk C., Nakajima-Sasaki R., Pablo J., Molina D.M., Hirst S., Chew J.S., Wang D., Tan G., Duffield M., Yang R., Neel J., Chantratita N., Bancroft G., Lertmemongkolchai G., Davies D.H., Baldi P., Peacock S., Titball R.W. A Burkholderia pseudomallei protein microarray reveals serodiagnostic and cross-reactive antigens. Proc. Natl. Acad. Sci. U.S.A. 2009, 106(32):13499-13504.
13. Gardy J.L., Laird M.R., Chen F., Rey S., Walsh C.J., Ester M., Brinkman F.S. PSORTb v.2.0: expanded prediction of bacterial protein subcellular localization and insights gained from comparative proteome analysis. Bioinformatics 2005, 21(5):617-623.
14. Gardy J.L., Spencer C., Wang K., Ester M., Tusnady G.E., Simon I., Hua S., deFays K., Lambert C., Nakai K., Brinkman F.S. PSORT-B: improving protein subcellular localization prediction for Gram-negative bacteria. Nucleic Acids Res. 2003, 31(13):3613-3617.
15. Havlasova J., Hernychova L., Brychta M., Hubalek M., Lenco J., Larsson P., Lundqvist M., Forsman M., Krocova Z., Stulik J., Macela A. Proteomic analysis of anti-Francisella tularensis LVS antibody response in murine model of tularemia. Proteomics 2005, 5(8):2090-2103.
16. Havlasova J., Hernychova L., Halada P., Pellantova V., Krejsek J., Stulik J., Macela A., Jungblut P.R., Larsson P., Forsman M. Mapping of immunoreactive antigens of Francisella tularensis live vaccine strain. Proteomics 2002, 2(7):857-867.
17. Hornick R.B., Dawkins A.T., Eigelsbach H.T., Tulis J.J. Oral tularemia vaccine in man. Antimicrobial. Agents Chemother. (Bethesda) 1966, 6:11-14.
18. Hornick R.B., Eigelsbach H.T. Aerogenic immunization of man with live Tularemia vaccine. Bacteriol. Rev. 1966, 30(3):532-538.
19. Janovska S., Pavkova I., Hubalek M., Lenco J., Macela A., Stulik J. Identification of immunoreactive antigens in membrane proteins enriched fraction from Francisella tularensis LVS. Immunol. Lett. 2007, 108:151-159.
20. Janovska S., Pavkova I., Reichelova M., Hubaleka M., Stulik J., Macela A. Proteomic analysis of antibody response in a case of laboratory-acquired infection with Francisella tularensis subsp. tularensis. Folia Microbiol. (Praha) 2007, 52:194-198.
21. Kirimanjeswara G.S., Olmos S., Bakshi C.S., Metzger D.W. Humoral and cell-mediated immunity to the intracellular pathogen Francisella tularensis. Immunol. Rev. 2008, 225:244-255.
22. Kortepeter M.G., Parker G.W. Potential biological weapons threats. Emerg. Infect. Dis. 1999, 5(4):523-527.
23. Mansfield M.A. Rapid immunodetection on polyvinylidene fluoride membrane blots without blocking. Anal. Biochem. 1995, 229(1):140-143.
24. Matyas B.T., Nieder H.S., Telford S.R. III Pneumonic tularemia on Martha's Vineyard: clinical, epidemiologic, and ecological characteristics. Ann. N.Y. Acad. Sci. 2007, 351-377. 1105.
25. Oyston P.C., Quarry J.E. Tularemia vaccine: past, present and future. Antonie Van Leeuwenhoek 2005, 87(4):277-281.
26. Pasetti M.F., Cuberos L., Horn T.L., Shearer J.D., Matthews S.J., House R.V., Sztein M.B. An improved Francisella tularensis live vaccine strain (LVS) is well tolerated and highly immunogenic when administered to rabbits in escalating doses using various immunization routes. Vaccine 2008, 26(14):1773-1785.
27. Rey S., Acab M., Gardy J.L., Laird M.R., deFays K., Lambert C., Brinkman F.S. PSORTdb: a protein subcellular localization database for bacteria. Nucleic Acids Res. 2005, 33(Database issue):D164-D168.
28. Saslaw S., Carhart S. Studies with tularemia vaccines in volunteers. III. Serologic aspects following intracutaneous or respiratory challenge in both vaccinated and nonvaccinated volunteers. Am. J. Med. Sci. 1961, 241:689-699.
29. Saslaw S., Eigelsbach H.T., Prior J.A., Wilson H.E., Carhart S. Tularemia vaccine study. II. Respiratory challenge. Arch. Intern. Med. 1961, 107:702-714.
30. Saslaw S., Eigelsbach H.T., Wilson H.E., Prior J.A., Carhart S. Tularemia vaccine study. I. Intracutaneous challenge. Arch. Intern. Med. 1961, 107:689-701.
31. Sjostedt A. Family XVII. FRANCISELLACEAE Genus I. Francisella. Bergery's Manual of Systemic Bacteriology 2001, Springer, New York. D.J. Brenner (Ed.).
32. Sjostedt A. Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann. N.Y. Acad. Sci. 2007, 1105:1-29.
33. Sundaresh S., Randall A., Unal B., Petersen J.M., Belisle J.T., Hartley M.G., Duffield M., Titball R.W., Davies D.H., Felgner P.L., Baldi P. From protein microarrays to diagnostic antigen discovery: a study of the pathogen Francisella tularensis. Bioinformatics 2007, 23(13):i508-i518.
34. Tarnvik A. Nature of protective immunity to Francisella tularensis. Rev. Infect. Dis. 1989, 11(3):440-451.
35. Titball R.W., Oyston P.C. A vaccine for tularaemia. Expert Opin. Biol. Ther. 2003, 3(4):645-653.
36. Twine S.M., Mykytczuk N.C., Petit M., Tremblay T.L., Conlan J.W., Kelly J.F. Francisella tularensis proteome: low levels of ASB-14 facilitate the visualization of membrane proteins in total protein extracts. J. Proteome. Res. 2005, 4(5):1848-1854.
37. Twine S.M., Petit M.D., Fulton K.M., House R.V., Conlan J.W. Immunoproteomics analysis of the murine antibody response to vaccination with an improved Francisella tularensis live vaccine strain (LVS). PLoS. One 2010, 5(4):e10000.
38. Twine S.M., Petit M.D., Shen H., Mykytczuk N.C., Kelly J.F., Conlan J.W. Immunoproteomic analysis of the murine antibody response to successful and failed immunization with live anti-Francisella vaccines. Biochem. Biophys. Res. Commun. 2006, 346(3):999-1008.
39. Viljanen M.K., Nurmi T., Salminen A. Enzyme-linked immunosorbent assay (ELISA) with bacterial sonicate antigen for IgM, IgA, and IgG antibodies to Francisella tularensis: comparison with bacterial agglutination test and ELISA with lipopolysaccharide antigen. J. Infect. Dis. 1983, 148(4):715-720.